Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
2015 · JNCI Journal of the National Cancer Institute · 120 citations
https://doi.org/10.1093/jnci/djv369
A
Ann C. Mladek
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
233
Papers
2.5K
Citations
26
h-index
39
i10-index
Ann C. Mladek is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Glioma Diagnosis and Treatment & PARP inhibition in cancer therapy & Cancer therapeutics and mechanisms. The author has an h-index of 26, co-authored 199 publications.
ORCID: 0000-0002-0508-6531Papers by this author
worksDisruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells
2005 · Neoplasia · 94 citations
https://doi.org/10.1593/neo.05361
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins
2016 · Cell Reports · 74 citations
https://doi.org/10.1016/j.celrep.2016.02.045
Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities
2021 · Cell Reports · 10 citations
https://doi.org/10.1016/j.celrep.2021.110054
Figure S8 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935413
Figure S5 from Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma
2024 · 0 citations
https://doi.org/10.1158/1535-7163.24935422.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat